Q32 Bio Clinical Trial Data
Q32 Bio presented additional 36-week results and initial 16-week off-drug findings from its SIGNAL-AA Phase 2a trial of bempikibart in patients with severe alopecia areata. The data showed clinically meaningful efficacy, including a 35.3% mean reduction in SALT scores, and supported the drug's advancement into a registration-directed program in the first half of 2027.
“Bempikibart’s robust efficacy data and durability observed across the 36-week treatment period and 16-week off-drug period in both JAK inhibitor-experienced and JAK inhibitor-naïve patients, changes on biomarkers supportive of its bifunctional mechanism, and its favorable safety and tolerability profile support its continued development in a registration-directed program in patients with severe or very severe alopecia areata as well as in expanded alopecia areata populations and other autoimmune and inflammatory indications.”
Jodie Morrison, Chief Executive Officer of Q32 Bio